- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- Multivitamin-no intervention
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 200 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 16,401
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
- Interventions
- Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care
- Other · Behavioral · Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Brain Tumor, Central Nervous System Tumor
- Interventions
- lomustine, temozolomide
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Chronic Pain, Peripheral Neuropathy, Nervous System Diseases, Peripheral Nervous System Diseases, Peripheral Nervous System Problem, Peripheral Nerve Injuries, Peripheral Nervous
- Interventions
- StimRouter Neuromodulation System
- Device
- Lead sponsor
- Bioness Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 9
- States / cities
- La Jolla, California • Larkspur, California • Redwood City, California + 6 more
- Conditions
- Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers, Gynecologic Cancers, Head and Neck Cancers, Melanoma, Thoracic Cancers
- Interventions
- IGF-Methotrexate conjugate
- Drug
- Lead sponsor
- IGF Oncology, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Dystonic Cerebral Palsy
- Interventions
- ITB Titration Protocol, Ventral Dorsal Rhizotomy, Deep Brain Stimulation, Research Assessments and Study Monitoring
- Drug · Procedure · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- ALK Fusion-positive Solid or CNS Tumors
- Interventions
- Alectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 7
- States / cities
- Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
- Interventions
- BPX-501 and Rimiducid
- Biological
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 4 Months to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prevention & Control
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27,395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
- Conditions
- Infectious Metabolic Encephalopathy, Ischemic Stroke, Seizure, Viral Encephalitis, Small and Large Vessel
- Interventions
- keypresses
- Behavioral
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Limb-Girdle Muscular Dystrophy, Type 2E
- Interventions
- SRP-9003
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 15 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Spinal Cord Injuries (SCI), Multiple Sclerosis
- Interventions
- Individualized reduction of falls (iROLL), Stopping Elderly Accidents, Deaths & Injuries (STEADI)
- Procedure
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Stroke
- Interventions
- Sentinel® Cerebral Protection System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 37 more
- Conditions
- Huntington's Disease
- Interventions
- Not listed
- Lead sponsor
- University College, London
- Other
- Eligibility
- 11 Years to 75 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2017
- U.S. locations
- 6
- States / cities
- Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
- Conditions
- Parkinson Disease, Tremor
- Interventions
- Istradefylline Pill
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- McLean, Virginia
- Conditions
- Obstructive Sleep Apnea, Spinal Cord Injuries
- Interventions
- Mild intermittent hypoxia, Sham protocol, Continuous positive airway pressure (CPAP)
- Other
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Detroit, Michigan
- Conditions
- Reversible Cerebral Vasoconstriction Syndrome
- Interventions
- TCD- cerebral blood flow velocities, Headache pain score, Neurological examination, Repeat Neuroimaging, Nimodipine, Verapamil ER
- Diagnostic Test · Behavioral · Other + 1 more
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Dementia
- Interventions
- Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day, Oral Placebo
- Drug
- Lead sponsor
- Woolsey Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Stamford, Connecticut • Lakeland, Florida • Miami Lakes, Florida + 3 more
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
- Biological · Drug
- Lead sponsor
- Bruce Cree
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Parkinson Disease
- Interventions
- Virtual reality bicycling
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Epilepsy, Complex Partial
- Interventions
- Zonisamide
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- TV-1106, Recombinant human growth hormone
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 23 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
- Interventions
- Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
- Drug · Other
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 6 Years to 28 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Parkinson's Disease
- Interventions
- Standard of Care, Home Visit Program (HVP)
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York